Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial.
Kazuma OyamaItamar RazAvivit CahnJulia KuderSabina A MurphyDeepak L BhattLawrence Alan LeiterDarren K McGuireJohn P H WildingKyong-Soo ParkAssen GoudevRafael DiazJindřich ŠpinarIngrid A M Gause-NilssonOfri MosenzonMarc S SabatineStephen D WiviottPublished in: European heart journal (2021)
URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01730534.